Yoshihiko Taniguchi

Sakai, 5918555, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 71 publications

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Journal: American journal of respiratory and critical care medicine

Published: January 25, 2026

Severe coronary artery spasm associated with endobronchial cytologic sampling, bleeding, and endobronchial epinephrine administration during bronchoscopy: A case report.

Severe coronary artery spasm associated with endobronchial cytologic sampling, bleeding, and endobronchial epinephrine administration during bronchoscopy: A case report.

Journal: Respiratory medicine case reports

Published: December 18, 2025

Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment.

Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment.

Journal: Anticancer research

Published: July 29, 2025

Minimal Clinically Important Difference in the Integrated Palliative Care Outcome Scale for Cancer Dyspnea.

Minimal Clinically Important Difference in the Integrated Palliative Care Outcome Scale for Cancer Dyspnea.

Journal: Journal of pain and symptom management

Published: April 24, 2025

Real-world Data of the Lung Cancer Compact Panel™ in Non-small Cell Lung Cancer Using Tissue Samples.

Real-world Data of the Lung Cancer Compact Panel™ in Non-small Cell Lung Cancer Using Tissue Samples.

Journal: Anticancer research

Published: March 07, 2025

Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.

Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 28, 2024

Case of a rare EGFR mutation L747P identified using the lung cancer compact Panel™ leading to successful Afatinib treatment.

Case of a rare EGFR mutation L747P identified using the lung cancer compact Panel™ leading to successful Afatinib treatment.

Journal: Respiratory medicine case reports

Published: December 22, 2024

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.

Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA.

Journal: Investigational new drugs

Published: December 13, 2024

Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.

Circulating Tumour DNA in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer and Early Disease Progression After First-Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study.

Journal: Cancer medicine

Published: December 08, 2024

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 22, 2024

Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.

Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: July 22, 2024

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 07, 2024

Showing 1-12 of 71

Last Updated: 09/26/2026